Cloning

Matchis Foundation Improves Life-Saving Stem Cell Donation Processes with K2

Retrieved on: 
Wednesday, October 7, 2020
Branches of biology, Biology, Life sciences, Biotechnology, Cell biology, Cloning, Developmental biology, Stem cell

The use of K2 has enabled the Matchis Foundation to drive operational efficiencies at many different stages in the administrative process.

Key Points: 
  • The use of K2 has enabled the Matchis Foundation to drive operational efficiencies at many different stages in the administrative process.
  • "K2 enables us to process an increasing number of stem cell donor requests with the same sized team and help more patients to receive life-saving stem cell replacement treatments," said Karin Butter, donor services team leader at Matchis Foundation.
  • "We are proud to partner with Indocs to help the Matchis Foundation streamline its processes and provide transparency across all activities," said Andrew Murphy, vice president, EMEA at K2.
  • The K2 donor services solution was developed for the Matchis Foundation by Indocs, a K2 partner based in the Netherlands.

Matchis Foundation Improves Life-Saving Stem Cell Donation Processes with K2

Retrieved on: 
Wednesday, October 7, 2020
Branches of biology, Biology, Life sciences, Biotechnology, Cell biology, Cloning, Developmental biology, Stem cell

The use of K2 has enabled the Matchis Foundation to drive operational efficiencies at many different stages in the administrative process.

Key Points: 
  • The use of K2 has enabled the Matchis Foundation to drive operational efficiencies at many different stages in the administrative process.
  • "K2 enables us to process an increasing number of stem cell donor requests with the same sized team and help more patients to receive life-saving stem cell replacement treatments," said Karin Butter, donor services team leader at Matchis Foundation.
  • "We are proud to partner with Indocs to help the Matchis Foundation streamline its processes and provide transparency across all activities," said Andrew Murphy, vice president, EMEA at K2.
  • The K2 donor services solution was developed for the Matchis Foundation by Indocs, a K2 partner based in the Netherlands.

Stem Cell Daily News Service - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 7, 2020
Health, Stem cells, Branches of biology, Biology, Life sciences, Biotechnology, Stem cells, Cloning, Developmental biology

The "Stem Cell Daily" newsletter has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Stem Cell Daily" newsletter has been added to ResearchAndMarkets.com's offering.
  • Stem Cell Daily includes the latest peer-reviewed research, patent filings, clinical trials, and policy developments on stem cell science and application.
  • For over 30 years, the analyst has monitored and reported on the world's emerging research and discoveries every day.
  • Their original content is reported from sources of unparalleled depth according to the highest standards of journalism.

Addressing the Malvertising Trend of Malicious Cloned Sites, GeoEdge is the 1st Ad Security Solution to Block Ads leading to Cloned Sites to Protect Publishers & Users

Retrieved on: 
Tuesday, October 6, 2020
Online advertising, Advertising, Marketing, Branches of biology, Malvertising, Cloning, Ad blocking

Malicious advertisers can buy a cloned website template for a few dollars and use IP addresses to more effectively target users.

Key Points: 
  • Malicious advertisers can buy a cloned website template for a few dollars and use IP addresses to more effectively target users.
  • To address the shift to content-driven malvertising, GeoEdge becomes the first ad security solution to offer publishers and platforms a way to block serving any ad leading to a landing page from a malicious cloned website in real-time.
  • By blocking these ads leading to cloned websites, GeoEdge eliminates the threat of malicious ad attacks before a user is exposed to the ad.
  • Leading publishers, ad platforms, exchanges, and networks rely on GeoEdge's automated ad verification solutions to monitor and protect their ad inventory without sacrificing revenue.

BrainStorm Announces Scientific Presentation at the Annual NEALS Meeting

Retrieved on: 
Wednesday, September 30, 2020
Branches of biology, Biology, Life sciences, Biotechnology, Cell biology, Cloning, Developmental biology, Stem cell

To achieve its goal, NEALS functions as an academic research consortium, a contracted research organization, and a resource tool for the ALS community.

Key Points: 
  • To achieve its goal, NEALS functions as an academic research consortium, a contracted research organization, and a resource tool for the ALS community.
  • NEALS is committed to the principles of open scientific communication, peer review, full and open disclosure of potential conflicts of interest, and democratic governance of its organization and activities.
  • About BrainStorm Cell Therapeutics Inc.
    BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases.
  • BrainStorm is also conducting an FDA-approved phase 2 open-label multicenter trial in progressive multiple sclerosis (MS).

Orchard Therapeutics Receives EMA PRIME Designation for OTL-203 for the Treatment of MPS-I

Retrieved on: 
Monday, September 28, 2020
Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Transplantation medicine, Cloning, Developmental biology, Hematopoietic stem cell, Enzyme replacement therapy, Therapy, Gene therapy

Orchard expects to release full proof-of-concept results at one year and initiate a registrational study for OTL-203 in 2021.

Key Points: 
  • Orchard expects to release full proof-of-concept results at one year and initiate a registrational study for OTL-203 in 2021.
  • Treatment options for MPS-I include hematopoietic stem cell transplant and chronic enzyme replacement therapy, both of which have significant limitations.
  • OTL-203 is an investigationalex vivoautologous hematopoietic stem cell gene therapy being studied for the treatment of MPS-I.
  • The information that Orchard posts on these channels and websites could be deemed to be material information.

FDA Grants IND Approval for Phase II Clinical Trial Using Stemedica's itMSC Therapy for COVID-19 Patients

Retrieved on: 
Monday, September 28, 2020
Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Cloning, Developmental biology, Stem-cell therapy, Hypoxia, COVID-19 drug repurposing research

The study will enroll up to 40 patients into two cohorts, randomized 1:1 to receive the active study drug plusstandardtreatmentorplacebo(lactate ringer solution)plusstandardtreatment.

Key Points: 
  • The study will enroll up to 40 patients into two cohorts, randomized 1:1 to receive the active study drug plusstandardtreatmentorplacebo(lactate ringer solution)plusstandardtreatment.
  • The stem cell treatment resulted in an improved clinical course for the patients.
  • Within 24-48 hours of receiving the stem cells, all patients had a significant reduction in oxygen requirements.
  • "This results in less damage to the lungs and a better clinical outcome for COVID-19 patients, in particular, for breathing capability."

Meso Numismatics Update On Global Stem Cells Group Acquisition

Retrieved on: 
Friday, September 18, 2020
Branches of biology, Biology, Life sciences, Induced stem cells, Biotechnology, Cell biology, Cloning, Developmental biology, Stem cell

We are close to submitting our past due filings with the SEC and now, with this payment, one step closer in completing the acquisition of Global Stem Cells Group, said David Christensen, CEO and President of the Company.

Key Points: 
  • We are close to submitting our past due filings with the SEC and now, with this payment, one step closer in completing the acquisition of Global Stem Cells Group, said David Christensen, CEO and President of the Company.
  • We maintain our continued optimism for the opportunities that Global Stem Cell Group brings to Stem Cell Bio Technology and the future that GSCG will play in Regenerative Medicine.
  • For more information on Global Stem Cells Group please visit: www.stemcellsgroup.com
    About Meso Numismatics: Meso Numismatics, Corp is an emerging numismatic and technology company specialized in the Meso Region, including Central America and the Caribbean.
  • Lans Holdings Inc. disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.

Therapeutic Solutions International Files Comprehensive Campbell Platform™ Patent for Stem Cell Immunotherapy of Schizophrenia

Retrieved on: 
Monday, September 14, 2020
Branches of biology, Biology, Life sciences, Biotechnology, Cell biology, Cloning, Cancer immunotherapy, Immunotherapy, Virotherapy, Stem cell

OCEANSIDE, Calif., Sept. 14, 2020 /PRNewswire/ --Therapeutics Solution International, Inc., (OTC Markets: TSOI), announced today filing of a landmark patent, with over 1000 claims, covering stem cell based immunotherapy of schizophrenia, one of the significant causes of suicide.

Key Points: 
  • OCEANSIDE, Calif., Sept. 14, 2020 /PRNewswire/ --Therapeutics Solution International, Inc., (OTC Markets: TSOI), announced today filing of a landmark patent, with over 1000 claims, covering stem cell based immunotherapy of schizophrenia, one of the significant causes of suicide.
  • "We are proud to have developed a novel, science-based, platform for therapeutic intervention which is grounded in objective assessment and intervention methods."
  • In December 2018 Therapeutic Solutions International signed an agreement with Jadi Cell LLC for licensing of the JadiCell universal donor adult stem cell, as covered in US Patent No.
  • Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases.

Establishing New Standards in Efficient Single Cell Cloning of hiPSCs, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Wednesday, September 9, 2020
Branches of biology, Biology, Life sciences, Induced stem cells, Stem cells, Biotechnology, Induced pluripotent stem cell, Cloning

Drug discovery, diagnostic and therapeutic efforts are increasingly using human-induced pluripotent stem cells (hiPSCs) and related technologies.

Key Points: 
  • Drug discovery, diagnostic and therapeutic efforts are increasingly using human-induced pluripotent stem cells (hiPSCs) and related technologies.
  • However, the inability to robustly manipulate hiPSCs as single cells has remained a significant biological and technical hurdle.
  • For more information or to register for this event, visit Establishing New Standards in Efficient Single Cell Cloning of hiPSCs .
  • Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.